P62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA

Oncogene

Volumn 36, Issue 3, 2017, Pages 304-317

  Xu, L Z ^a,b   Li, S S ^a,b   Zhou, W ^a,b   Kang, Z J ^a,b   Zhang, Q X ^c   Kamran, M ^a,b   Xu, J ^a,b   Liang, D P ^a,b   Wang, C L ^a,b   Hou, Z J ^a,b   Wan, X B ^d   Wang, H J ^a   Lam, E W F ^e   Zhao, Z W ^a   Liu, Q ^a,b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CD24 ANTIGEN; HERMES ANTIGEN; MESSENGER RNA; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; SEQUESTOSOME 1; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; MICRORNA; MIRNLET7 MICRORNA, HUMAN; MYC PROTEIN, HUMAN; SQSTM1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST EPITHELIUM CELL; CANCER PROGNOSIS; CANCER STEM CELL; COLONY FORMATION; CONTROLLED STUDY; GENE DELETION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MIDDLE AGED; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA DEGRADATION; RNA PROCESSING; RNA STABILITY; RNA TRANSCRIPTION; STEM CELL SELF-RENEWAL; TUMOR GROWTH; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CHEMISTRY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICE; MICRORNAS; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RNA STABILITY; RNA, MESSENGER; SEQUESTOSOME-1 PROTEIN; UP-REGULATION;

EID: 84976299538     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.202     Document Type: Article

References (62)

1. Gaffan J, Dacre J, Jones A. Educating undergraduate medical students about oncology: a literature review. J Clin Oncol 2006; 24: 1932-1939.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
4. Filipova A, Seifrtova M, Mokry J, Dvorak J, Rezacova M, Filip S et al. Breast cancer and cancer stem cells: a mini-review. Tumori 2014; 100: 363-369.
5. Nigam A. Breast cancer stem cells, pathways and therapeutic perspectives 2011. Indian J Surg 2013; 75: 170-180.
6. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
7. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567.
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
9. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332-2336.
10. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
11. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004; 23: 7267-7273.
12. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
13. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328-9337.
14. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
15. Li C, Lee CJ, Simeone DM. Identification of human pancreatic cancer stem cells. Methods Mol Biol 2009; 568: 161-173.
16. Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R Jr., Badve S et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24-phenotype. BMC Cancer 2010; 10: 411.
17. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11: 259-273.
18. Lin Y, Zhong Y, Guan H, Zhang X, Sun Q. CD44+/CD24-phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma. J Exp Clin Cancer Res 2012; 31: 59.
19. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25.
20. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98: 1777-1785.
21. Zheng FM, Long ZJ, Hou ZJ, Luo Y, Xu LZ, Xia JL et al. A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance. Mol Cancer Ther 2014; 13: 1991-2003.
22. Vadlamudi RK, Joung I, Strominger JL, Shin J. p62, a phosphotyrosineindependent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem 1996; 271: 20235-20237.
23. Ichimura Y, Waguri S, Sou YS, Kageyama S, Hasegawa J, Ishimura R et al. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell 2013; 51: 618-631.
24. Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 2008; 13: 343-354.
25. Moscat J, Diaz-Meco MT. The atypical protein kinase Cs. Functional specificity mediated by specific protein adapters. EMBO Rep 2000; 1: 399-403.
26. Duran A, Amanchy R, Linares JF, Joshi J, Abu-Baker S, Porollo et al. p62 is a key regulator of nutrient sensing in the mTORC1 pathway. Mol Cell 2011; 44: 134-146.
27. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282: 24131-24145.
28. Kitamura H, Torigoe T, Asanuma H, Hisasue SI, Suzuki K, Tsukamoto T et al. Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue. Histopathology 2006; 48: 157-161.
29. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21: 105-120.
30. Inoue D, Suzuki T, Mitsuishi Y, Miki Y, Suzuki S, Sugawara S et al. Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci 2012; 103: 760-766.
31. Galavotti S, Bartesaghi S, Faccenda D, Shaked-Rabi M, Sanzone S, McEvoy et al. The autophagy-Associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene 2013; 32: 699-712.
32. Li L, Shen C, Nakamura E, Ando K, Signoretti S, Beroukhim R et al. SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell 2013; 24: 738-750.
33. Thompson HG, Harris JW, Wold BJ, Lin F, Brody JP. p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells. Oncogene 2003; 22: 2322-2333.
34. Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R, Spendlove I. The ubiquitinbinding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer 2007; 14: 73-80.
35. Luo RZ, Yuan ZY, Li M, Xi SY, Fu J, He J. Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer. OncoTargets Ther 2013; 6: 883-888.
36. Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K, Hino O et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol 2011; 193: 275-284.
37. Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AA, Kol N, Salmon-Divon M et al. Stem cells. m6A mRNA methylation facilitates resolution of naive pluripotency toward differentiation. Science 2015; 347: 1002-1006.
38. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
39. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
40. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 2010; 107: 10208-10213.
41. Yang X, Cai H, Liang Y, Chen L, Wang X, Si R et al. Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells. Oncol Rep 2015; 33: 1723-1730.
42. Liu Y, Yin B, Zhang C, Zhou L, Fan J. Hsa-let-7a functions as a tumor suppressor in renal cell carcinoma cell lines by targeting c-myc. Biochem Biophys Res Commun 2012; 417: 371-375.
43. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007; 67: 9762-9770.
44. Wong TS, Man OY, Tsang CM, Tsao SW, Tsang RK, Chan JY et al. MicroRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through downregulating c-Myc expression. J Cancer Res Clin Oncol 2011; 137: 415-422.
45. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39: 673-677.
46. Xia M, Yu H, Gu S, Xu Y, Su J, Li H et al. p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system. Int J Oncol 2014; 45: 2341-2348.
47. Linares JF, Amanchy R, Greis K, Diaz-Meco MT, Moscat J. Phosphorylation of p62 by cdk1 controls the timely transit of cells through mitosis and tumor cell proliferation. Mol Cell Biol2011; 31: 105-117.
48. Qiang L, Zhao B, Ming M, Wang N, He TC, Hwang S et al. Regulation of cell proliferation and migration by p62 through stabilization of Twist1. Proc Natl Acad Sci USA 2014; 111: 9241-9246.
49. Parkhitko A, Myachina F, Morrison TA, Hindi KM, Auricchio N, Karbowniczek M et al. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Proc Natl Acad Sci USA 2011; 108: 12455-12460.
50. Guan JL, Simon AK, Prescott M, Menendez JA, Liu F, Wang F et al. Autophagy in stem cells. Autophagy 2013; 9: 830-849.
51. Ioannidis P, Mahaira L, Papadopoulou A, Teixeira MR, Heim S, Andersen JA et al. CRD-BP: a c-Myc mRNA stabilizing protein with an oncofetal pattern of expression. Anticancer Res 2003; 23: 2179-2183.
52. Doyle GA, Betz NA, Leeds PF, Fleisig AJ, Prokipcak RD, Ross J. The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins. Nucleic Acids Res 1998; 26: 5036-5044.
53. Lemm I, Ross J. Regulation of c-myc mRNA decay by translational pausing in a coding region instability determinant. Mol Cell Biol 2002; 22: 3959-3969.
54. Weidensdorfer D, Stohr N, Baude A, Lederer M, Kohn M, Schierhorn et al. Control of c-myc mRNA stability by IGF2BP1-Associated cytoplasmic RNPs. RNA 2009; 15: 104-115.
55. Lafon I, Carballes F, Brewer G, Poiret M, Morello D. Developmental expression of AUF1 and HuR, two c-myc mRNA binding proteins. Oncogene 1998; 16: 3413-3421.
56. Kim HH, Kuwano Y, Srikantan S, Lee EK, Martindale JL, Gorospe M. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev 2009; 23: 1743-1748.
57. Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X et al. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem 2012; 287: 1527-1537.
58. Schmidt EV, Ravitz MJ, Chen L, Lynch M. Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway. Cell Cycle 2009; 8: 1344-1351.
59. Karunarathna U, Kongsema M, Zona S, Gong C, Cabrera E, Gomes AR et al. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance. Oncogene 2015; 35: 1433-1444.
60. Xu J, Wu X, Zhou WH, Liu AW, Wu JB, Deng JY et al. Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer. PLoS One 2013; 8: e56919.
61. Xu LZ, Long ZJ, Peng F, Liu Y, Xu J, Wang C et al. Aurora kinase a suppresses metabolic stress-induced autophagic cell death by activating mTOR signaling in breast cancer cells. Oncotarget 2014; 5: 7498-7511.
62. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.